Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Currently, novel psychoactive substance (NPS) use presents a challenging issue for authorities. To effectively tackle the use of NPS, a deeper understanding of the motivations of those who use NPS is required. Evidence suggests that a subset of NPS users declare their use as ‘self-medicating’; however, there is a paucity of research in this area. The aim of this review is to provide an overview and synthesis of the research concerning self-medication with novel psychoactive substances (NPS). Seven databases (EMBASE, MEDLINE, APA PsychInfo, Global Health, PubMed, Scopus, and Google Scholar) were searched using a search strategy compromising 600 + NPS terms, yielding 3563 articles, 24 of which met the search criteria. Two independent reviewers screened the articles and appraised the quality of the included studies. The results were synthesised using a narrative synthesis approach. We identified 22 NPS being used for self-medication. We found that (1) self-medication with NPS occurs mainly for anxiety, depression, and ADHD; (2) links between cluster headaches, the use of psychedelic NPS, and anxiety and novel benzodiazepines were evident; (3) novel benzodiazepine use by young individuals represents particular concern. There is a need for greater knowledge within healthcare professions concerning self-medication practices with NPS. Primary qualitative research is needed to address the underlying motivations behind this phenomenon.
Currently, novel psychoactive substance (NPS) use presents a challenging issue for authorities. To effectively tackle the use of NPS, a deeper understanding of the motivations of those who use NPS is required. Evidence suggests that a subset of NPS users declare their use as ‘self-medicating’; however, there is a paucity of research in this area. The aim of this review is to provide an overview and synthesis of the research concerning self-medication with novel psychoactive substances (NPS). Seven databases (EMBASE, MEDLINE, APA PsychInfo, Global Health, PubMed, Scopus, and Google Scholar) were searched using a search strategy compromising 600 + NPS terms, yielding 3563 articles, 24 of which met the search criteria. Two independent reviewers screened the articles and appraised the quality of the included studies. The results were synthesised using a narrative synthesis approach. We identified 22 NPS being used for self-medication. We found that (1) self-medication with NPS occurs mainly for anxiety, depression, and ADHD; (2) links between cluster headaches, the use of psychedelic NPS, and anxiety and novel benzodiazepines were evident; (3) novel benzodiazepine use by young individuals represents particular concern. There is a need for greater knowledge within healthcare professions concerning self-medication practices with NPS. Primary qualitative research is needed to address the underlying motivations behind this phenomenon.
Multiple drugs abuse/misuse/interactionVarious toxicities: case report A 38-year-old woman developed withdrawal symptoms after fentanyl and clonazepam withdrawal. Additionally, she developed altered mental status due to concomitant administration of phenibut and diphenhydramine, and paranoia and impulsivity following phenibut misuse and intoxication. Additionally, she had fentanyl, clonazepam and gabapentin abuse.The woman presented to an emergency department for trauma evaluation in March 2020 after falls from the 3 rd floor. Two days prior to the hospitalisation, she was self-treated with phenibut for anxiety, and fentanyl and clonazepam withdrawal management [dosage not stated]. She came to know about phenibut from her friend and purchased it via an online vendor. She reported injecting fentanyl 2 g/day, oral nonprescribed clonazepam 5-10 mg/day and nonprescribed oral gabapentin up to 2400mg twice daily. She had severe opioid, gabapentin and benzodiazepine use disorders and 8 months prior, she was treated with buprenorphine, which later stopped as she developed nausea and weight loss [aetiology not stated]. She had history of bipolar spectrum and posttraumatic stress disorders. Earlier, she was prescribed escitalopram, quetiapine and diphenhydramine. Five years prior to the admission, because of her suicidal and homicidal ideation, she was forcefully held in the ED for 3 days after a physical assault. Approximately 2 days prior to her current hospitalisation, she had ingested several teaspoons of phenibut (misuse). After her initial phenibut ingestion, she slept for about 24h. Her partner, who was supporting her self-directed detoxification, reported that upon awakening she showed impulsivity, paranoia and response to internal stimuli by engaging in self-dialogue. Thereafter, on the same day, she was brought to an ED after she left her house without clothes. On the same day, she was sent home; however, she was still not herself, reported by her partner. After back to the home, she ingested diphenhydramine and additional phenibut (quantity unknown). She slept briefly and was became aggressive and impulsive again. Subsequently, she jumped out of third story window, despite her partner's efforts to pull her back in. She was not able to remember the reason for jumping but did not intend to harm herself. On her presentation, she reported that difficulty ambulating with severe electric pain radiating down her spine. Her physical examination demonstrated thoracolumbar tenderness, mydriasis and decreased hip and knee flexor strength. Imaging showed severe spinal stenosis with unstable T12 and L1 fractures; therefore, she underwent emergent neurosurgery. Further, her urine toxicology was positive for fentanyl and benzodiazepines. On the standard hospital immunoassay, phenibut was not detected. Her urine sample was not sent for liquid chromatography/mass spectrometry analysis. She was treated based on her report of phenibut ingestion.The woman's hospital course was complicated by altered mental status which was consider...
Objectives: This systematic review aimed to identify published articles that evaluated all phenibut toxicity and withdrawal cases to understand better their clinical presentations and treatments. Methods: A comprehensive literature search was conducted using Medline (Ovid), Embase (Ovid), and Cochrane Library databases to capture all published cases on the presentations and management of phenibut toxicity or withdrawal. Results: Sixty-two cases from 36 studies on presentation and management of phenibut toxicity or phenibut withdrawal were identified. Of all subjects, 80.7% were male. The average age was 30.9 years (SD, 13.2 years; range, 0-71 years). A total of 86.8% reported obtaining phenibut online, and 63.2% reported concomitant substance use with other addictive agents; benzodiazepines and alcohol were the most combined drugs. The average length of hospital stay was 5.0 days (n = 25; SD, 5.4 days; range, 1-25 days) for phenibut toxicity and 7.7 days (n = 20; SD, 7.8 days; range, 0-30 days) for phenibut withdrawals. The most common symptoms reported during phenibut toxicity were altered mental status, somnolence, psychosis, and movement disorders. Of the phenibut toxicity cases, 48.7% required intubation. Benzodiazepines and antipsychotics were most used to treat phenibut toxicity. For phenibut withdrawal cases, 95.7% reported daily use. The most common symptoms reported during phenibut withdrawals were anxiety, irritability or agitation, insomnia, and psychosis. Sixteen (69.6%) of phenibut withdrawal cases required multiple medications for treatment. Benzodiazepines, baclofen, atypical antipsychotics, gabapentanoids, and barbiturates were commonly used to treat phenibut withdrawals. Conclusions: The seriousness of presentations, combined with the assortments of medications used for both syndromes, reflects the potential dangers of phenibut use and the need for systematized treatment protocols.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.